Why HUL and USV Both Bought Supplement Brands on the Same Day: Inside India's 2026 Nutrition Consolidation
Two Deals, One Day, and a Pattern Three Years Older Than It Looks
On February 12, 2026, Hindustan Unilever and USV Private Limited each announced acquisitions in India's D2C nutrition space within the same news cycle. HUL paid ₹824 crore for the remaining 49% of OZiva's parent company, Zywie Ventures, taking it to full ownership, while USV paid ₹1,583 crore, roughly $190 million, for a 79% stake in Wellbeing Nutrition.
Neither deal was actually the category's opening move. Marico had already taken majority control of Plix, through its parent Satiya Nutraceuticals, back in July 2023 for ₹369 crore, an earlier version of the same pattern now playing out at a larger scale.
What connects all three targets has less to do with revenue size and more to do with brand identity: a clean-label, science-positioned reputation that takes a large, slower-moving company years to build on its own, and that an acquisition buys in a single transaction.
USV's stated rationale for the Wellbeing Nutrition deal leans specifically into the GLP-1 and weight-management opportunity. Joint development of oral GLP-1 delivery systems and sarcopenia-focused protein products is explicitly part of the plan.
The scale behind all of this: India's dietary supplements market was valued at roughly ₹201 billion in 2025 and is projected to reach ₹573 billion by 2034, about 12.3% CAGR, which is the actual opportunity driving this round of consolidation.
For a consumer, none of this automatically makes a brand's products better or worse. It typically means more manufacturing and distribution muscle behind the brand, and a real, usually gradual, chance of formulation, pricing, or SKU changes as integration plays out. The one thing worth checking for yourself, regardless of who owns a brand, is whether it actually publishes batch-level testing data rather than just marketing language about purity.
The Deals, By the Numbers
Three transactions, three different structures, one shared category. Here's what's actually on record for each.
| Deal | Date | Acquirer | Target | Stake acquired | Deal value | Structure |
|---|---|---|---|---|---|---|
| Marico – Plix | July 26, 2023 (initial tranche; further stages through 2025) | Marico Limited | Satiya Nutraceuticals (parent of Plix) | 58% total (32.75% in the first tranche, taking majority board control) | ₹369 crore | Primary infusion plus secondary buyout; rights to acquire the balance over time |
| HUL – OZiva | February 12, 2026 | Hindustan Unilever | Zywie Ventures (parent of OZiva) | Remaining 49% (HUL already held 51% from an earlier deal) | ₹824 crore | OZiva becomes a wholly owned HUL subsidiary |
| USV – Wellbeing Nutrition | February 12, 2026 | USV Private Limited | Wellbeing Nutrition | 79% | ₹1,583 crore (~$190 million) | All-cash; founder Avnish Chhabria retains roughly 21% alongside employees until 2028, when USV takes full ownership |
One more detail from the same announcement window worth noting: on the same day as the OZiva deal closed out, HUL also sold a 19.8% stake in Nutritionalab (a separate HUL nutrition investment) to USV for ₹307 crore. So the two headline deals weren't fully separate stories, there was a small piece of cross-over inventory changing hands between the two acquirers on the very same day.
For scale, OZiva itself had grown to roughly ₹480 crore in revenue in 2025, at close to 130% compound annual growth over the two years since HUL first took a majority stake in it, according to HUL's own announcement. That growth trajectory is very likely a meaningful part of why HUL chose to close out full ownership now rather than staying at a 51% stake indefinitely.
The Pattern Started Quietly in 2023
HUL and USV announcing deals on the same day looks like coincidence at first glance. Looked at over a longer window, it reads more like the visible, compressed moment of a pattern that's been building since at least mid-2023.
Marico's move into Plix wasn't presented at the time as a category-defining event. It was one FMCG major buying into one digital-first nutrition brand, structured in stages rather than a single clean buyout: an initial 32.75% for board control in July 2023, with the path to the full 58% (and eventually more) spread out through 2025. Marico's own CEO, Saugata Gupta, framed the logic at the time as expanding "total addressable market in value-added wellness foods and nutrition segments" while bringing in "another digital-first brand with a distinct value proposition." Read three years later, that's a fairly precise description of what HUL and USV each said about their own deals in February 2026.
What changed between 2023 and 2026 wasn't the logic, it was the pace. HUL's own announcement was explicit that OZiva's growth (roughly 130% CAGR over two years, scaling past ₹480 crore in 2025) is what justified moving from a 51% stake to full ownership now rather than later. USV's language around Wellbeing Nutrition leaned on a similar idea, but forward-looking: building what it called a "future-facing healthcare portfolio" rather than simply absorbing an existing one. HUL CEO Priya Nair described the company's current approach as "fewer, bigger bets where we can leverage HUL's strengths in science, distribution and market development," which is a useful way to read all three deals together: these aren't scattershot investments, they're each company picking one or two nutrition brands they believe already have the credibility and product-market fit, and then applying scale to what was already working.
What actually explains February 2026 is a pattern that started quietly back in 2023, not three acquisitions that simply happened to land in the same year. Two of them arriving within the same 24 hours is what finally made it impossible to miss.
What's Actually Being Bought
Revenue size alone doesn't explain why Plix, OZiva, and Wellbeing Nutrition were the ones bought, none of the three was India's single largest-revenue D2C nutrition brand at the time. Brand equity is the better explanation: a clean-label, ingredient-forward, digitally native identity that's genuinely hard and slow for a large, legacy company to build internally, and that a wellness-literate, label-reading customer base already trusts.
That's a different asset than distribution, manufacturing capacity, or raw revenue, and it's precisely the asset a company like HUL or Marico already has in abundance. A large FMCG player can scale production and shelf presence in a matter of quarters. What it can't do quickly is convince a 28-year-old who reads ingredient labels and compares protein sourcing across five Instagram-native brands that a 100-year-old soap-and-shampoo company suddenly "gets" clean nutrition. Buying the brand that already earned that trust is faster, and in the FMCG playbook, often cheaper, than trying to build it from inside a legacy portfolio.
Ingredients and formulations barely factor into what's actually changing hands here. Wellbeing Nutrition, OZiva, and Plix each carry distinct product catalogues and distinct customer relationships, and what USV and HUL are paying for is the brand relationship and the operating team behind it, not a recipe. That's also why these deals kept founders in place, and in Wellbeing Nutrition's case left a meaningful minority stake with the founder through a multi-year transition rather than a clean, immediate full buyout: credibility holds up better absorbed gradually than rebadged overnight.
Why Now
Three things are converging on this category at once, and each one independently would have been enough to draw acquirer interest.
The market itself is large and still accelerating. India's dietary supplements market was valued at roughly ₹201.46 billion in 2025 and is projected to reach ₹572.62 billion by 2034, a compound annual growth rate of about 12.3% from 2026 onward. That's not a niche category anymore, it's a market large enough that a single-digit share shift matters to a company the size of HUL or Marico at the balance-sheet level.
GLP-1 and weight-management adjacency is a specific, near-term driver, at least for USV. USV's own framing of the Wellbeing Nutrition deal names a concrete product roadmap rather than a general endorsement of the brand: jointly developing oral delivery systems for GLP-1 therapies, as an alternative to injectable formats, and clinical-grade protein products aimed at sarcopenia, the muscle loss that often accompanies rapid weight reduction. That's a pharma company using an acquired D2C brand as a distribution and consumer-trust channel into a therapeutic area it's already active in, a meaningfully different rationale than an FMCG company buying general wellness credibility.
D2C economics have gotten harder over the last few years, which changes what founders themselves want. Customer acquisition costs across performance marketing channels have climbed steadily industry-wide, and a founder-led brand that's built genuine trust with its customer base is sitting on an asset that's expensive to keep growing independently but very attractive to a buyer who already has the distribution and manufacturing scale to make that same trust more profitable. None of this is unique to Indian nutrition brands, it's the same logic that's driven consolidation in D2C categories globally, but the Indian supplement category is hitting that inflection point now, at the same time the market itself is large enough to justify billion-rupee-plus deals.
What Changes For You As a Customer
If you use products from any of these three brands, or you're watching this pattern and wondering what it means more broadly for the D2C supplement category you buy from, here's a realistic, non-alarmist read on what usually does and doesn't change.
In the near term, usually not much. Formulations, SKUs, and pricing typically hold steady through the first year or two of an integration. Acquirers generally don't want to disrupt the exact product experience that made the brand worth buying in the first place, at least not immediately.
Over a longer horizon, three things are worth watching. First, reformulation toward manufacturing efficiency at scale is common once a brand moves onto a parent company's supply chain, sometimes for the better (tighter quality control, more consistent sourcing) and sometimes simply for cost. Second, SKU rationalization: slower-selling variants often get quietly discontinued as the brand gets folded into a larger portfolio's logic. Third, pricing tends to shift over a multi-year horizon in whichever direction the parent company's broader category strategy points, not necessarily up or down in a predictable way.
One thing usually does improve: manufacturing and quality-control resourcing. A brand backed by a company the size of HUL, Marico, or a pharmaceutical manufacturer like USV typically gains access to more rigorous, better-resourced testing and compliance infrastructure than an independent D2C brand can afford to run at scale. That's a genuine, non-trivial upside of these deals for consumers, even as other things shift.
The practical takeaway doesn't actually change based on who owns the brand. Whether a supplement brand is independent or newly folded into a conglomerate, the same due-diligence habit applies: check whether the specific product and batch you're buying has real, published testing data behind it, not just a brand name you recognize or a claim of "purity" on the label. Ownership structure tells you very little about what's actually in the bottle you're holding; a Certificate of Analysis for that batch tells you a great deal more.
Where the Independents Fit
Consolidation in a category doesn't erase the independent brands in it, it usually just sharpens what independence is actually worth to a customer. Once three of the more visible science-positioned D2C nutrition brands in India are owned in majority or full part by a soap-and-FMCG major and a pharmaceutical company, the brands that remain founder-led and independent are the ones where a customer can still trace a straight line from the person running the company to the product on the shelf, with no portfolio-level strategy sitting in between.
That's the specific space CYNQ Superfoods occupies: an independent, single-origin superfood brand built on a science-first premise rather than an Ayurvedic or "ancient wisdom" one, with a published Certificate of Analysis behind its ingredient batches rather than a marketing claim standing in for one. It's a smaller bet than a HUL or a Marico by definition, but it's also one where the testing data and the sourcing decisions aren't several ownership layers removed from the person making them. Whether that trade-off (scale and resourcing on one side, direct traceability on the other) matters to a given customer is a genuinely personal call, not a settled argument either way. What's worth knowing is that it's a real trade-off, not just marketing language, and it's one worth checking for yourself against whatever brand you're actually buying from, independent or newly acquired.
Questions People Actually Ask
Were the HUL-OZiva and USV-Wellbeing Nutrition deals actually announced on the same day? Yes. Both were announced on February 12, 2026. HUL's own announcement also disclosed that, on the same day, it sold a 19.8% stake in a separate nutrition investment, Nutritionalab, to USV for ₹307 crore, so the two acquirers had more than one point of overlap that week.
Is the Marico-Plix deal part of the same 2026 wave? No, and it's worth being precise about this: Marico's acquisition of majority control in Plix (via its parent, Satiya Nutraceuticals) was announced in July 2023, with the deal structured in stages through 2025. It's better understood as the early, smaller-scale version of the same pattern that became much more visible in February 2026, not a third 2026 deal.
Why are pharmaceutical and FMCG companies specifically targeting D2C nutrition brands right now? Three factors line up at once: India's dietary supplements market is large and growing quickly (roughly ₹201 billion in 2025, projected toward ₹573 billion by 2034), certain deals have specific therapeutic-area logic (USV's GLP-1 and sarcopenia roadmap with Wellbeing Nutrition being the clearest example), and D2C customer acquisition economics have made an established brand relationship a more attractive asset to buy than to build from inside a legacy portfolio.
Does an acquisition mean a supplement brand's product quality will get better or worse? Neither outcome is automatic. Formulations and pricing typically hold steady in the near term. Over a longer horizon, quality control and testing infrastructure often improve under a larger parent company's resources, while SKU range and pricing can shift in either direction as the brand integrates into a broader portfolio strategy.
What should I actually check if a brand I use gets acquired, or if I'm choosing between an acquired brand and an independent one? Ownership structure alone doesn't tell you what's in the product. Check whether the specific SKU and batch you're buying has real, published testing data (a Certificate of Analysis, not just a purity claim) behind it. That check is worth doing regardless of who owns the brand.
Sources
HUL: Invests ₹824 crores to acquire remaining 49% stake in Zywie Ventures (OZiva); divests 19.8% holding in Nutritionalab, HUL's own official press release, February 2026
YourStory: USV buys 79% stake in Wellbeing Nutrition, February 2026
Inc42: Marico to acquire a majority stake in D2C nutrition brand Plix for INR 369 Cr, July 2023
Business Standard: Marico to acquire 58% stake in Satiya Nutraceuticals for Rs 369 cr, July 2023
IMARC Group: India Dietary Supplements Market Size & Share, market sizing and CAGR data, updated August 2026
This article reflects publicly reported deal terms as of the dates cited above. Deal structures with multi-year vesting or conditional tranches (noted where applicable) may evolve as those conditions are met.